580 related articles for article (PubMed ID: 20824769)
1. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
[TBL] [Abstract][Full Text] [Related]
2. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
4. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
[TBL] [Abstract][Full Text] [Related]
5. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
6. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
Stone GW; Ellis SG; Colombo A; Grube E; Popma JJ; Uchida T; Bleuit JS; Dawkins KD; Russell ME
JACC Cardiovasc Interv; 2011 May; 4(5):530-42. PubMed ID: 21596326
[TBL] [Abstract][Full Text] [Related]
8. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
9. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
[TBL] [Abstract][Full Text] [Related]
10. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
11. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
[TBL] [Abstract][Full Text] [Related]
12. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from the BELLO (balloon elution and late loss optimization) trial.
Giannini F; Latib A; Jabbour RJ; Costopoulos C; Chieffo A; Carlino M; Montorfano M; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
Cardiovasc Revasc Med; 2017; 18(1):4-9. PubMed ID: 28011243
[TBL] [Abstract][Full Text] [Related]
13. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
[TBL] [Abstract][Full Text] [Related]
14. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
[TBL] [Abstract][Full Text] [Related]
15. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
[TBL] [Abstract][Full Text] [Related]
16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
17. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial.
Hong SJ; Kim MH; Cha KS; Park HS; Chae SC; Hur SH; Gwon HC; Bae JH; Lim DS
Catheter Cardiovasc Interv; 2010 Dec; 76(7):924-33. PubMed ID: 20815045
[TBL] [Abstract][Full Text] [Related]
19. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
